EP Patent

EP0787722A1 — Substituted quinazoline derivatives

Assigned to Wyeth Holdings LLC · Expires 1997-08-06 · 29y expired

What this patent protects

This invention provides a compound having the formula wherein: X is phenyl which is optionally substituted; R and R 1 are each, independently, hydrogen, halogen, alkyl, alkoxy, hydroxy, or trifluoromethyl; R 2 is hydrogen, alkyl, alkoxy, hydroxy, trifluor…

USPTO Abstract

This invention provides a compound having the formula wherein: X is phenyl which is optionally substituted; R and R 1 are each, independently, hydrogen, halogen, alkyl, alkoxy, hydroxy, or trifluoromethyl; R 2 is hydrogen, alkyl, alkoxy, hydroxy, trifluoromethyl; Y is a radical selected from the group consisting of R 3 is independently hydrogen, alkyl, carboxy, carboalkoxy, phenyl, or carboalkyl; n = 2-4; or a pharmaceutically acceptable salt thereof, with the proviso that each R 3 of Y may be the same or different which are useful as antineoplastic agents.

Drugs covered by this patent

Patent Metadata

Patent number
EP0787722A1
Jurisdiction
EP
Classification
—
Expires
1997-08-06
Drug substance claim
No
Drug product claim
No
Assignee
Wyeth Holdings LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.